Clinical trials: Stable Nonsegmental Vitiligo
Vitiligo
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo.
- Trial name
- Tranquillo LTE (NCT06163326)
- Testing
- Ritlecitinib, Ritlecitinib 100 mg
- Where
- 73 sites in United States, Australia and 11 more
- Volunteers
- 394 people
- Sponsor
- Pfizer
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
- Trial name
- Tranquillo (NCT05583526)
- Testing
- Ritlecitinib
- Where
- 115 sites in United States, Australia and 13 more
- Volunteers
- 607 people
- Sponsor
- Pfizer